Muthu Sathish, Viswanathan Vibhu Krishnan, Sakthivel Manoharan, Thabrez Mohammed
Department of Orthopaedics, Orthopaedic Research Group, Coimbatore 641045, Tamil Nadu, India.
Department of Biotechnology, Karpagam Academy of Higher Education, Coimbatore 641021, Tamil Nadu, India.
World J Orthop. 2024 Mar 18;15(3):266-284. doi: 10.5312/wjo.v15.i3.266.
Multitudinous advancements have been made to the traditional microfracture (MFx) technique, which have involved delivery of various acellular 2 generation MFx and cellular MFx-III components to the area of cartilage defect. The relative benefits and pitfalls of these diverse modifications of MFx technique are still not widely understood.
To comparatively analyze the functional, radiological, and histological outcomes, and complications of various generations of MFx available for the treatment of cartilage defects.
A systematic review was performed using PubMed, EMBASE, Web of Science, Cochrane, and Scopus. Patients of any age and sex with cartilage defects undergoing any form of MFx were considered for analysis. We included only randomized controlled trials (RCTs) reporting functional, radiological, histological outcomes or complications of various generations of MFx for the management of cartilage defects. Network meta-analysis (NMA) was conducted in Stata and Cochrane's Confidence in NMA approach was utilized for appraisal of evidence.
Forty-four RCTs were included in the analysis with patients of mean age of 39.40 (± 9.46) years. Upon comparing the results of the other generations with MFX-I as a constant comparator, we noted a trend towards better pain control and functional outcome (KOOS, IKDC, and Cincinnati scores) at the end of 1-, 2-, and 5-year time points with MFx-III, although the differences were not statistically significant ( > 0.05). We also noted statistically significant Magnetic resonance observation of cartilage repair tissue score in the higher generations of microfracture (weighted mean difference: 17.44, 95% confidence interval: 0.72, 34.16, = 0.025; without significant heterogeneity) at 1 year. However, the difference was not maintained at 2 years. There was a trend towards better defect filling on MRI with the second and third generation MFx, although the difference was not statistically significant ( > 0.05).
The higher generations of traditional MFx technique utilizing acellular and cellular components to augment its potential in the management of cartilage defects has shown only marginal improvement in the clinical and radiological outcomes.
传统微骨折(MFx)技术已取得众多进展,包括将各种无细胞第二代MFx和细胞性MFx-III成分输送至软骨缺损区域。这些不同改良的MFx技术的相对益处和缺陷仍未得到广泛了解。
比较分析可用于治疗软骨缺损的各代MFx的功能、放射学和组织学结果以及并发症。
使用PubMed、EMBASE、科学网、Cochrane和Scopus进行系统评价。纳入任何年龄和性别的患有软骨缺损且接受任何形式MFx治疗的患者进行分析。我们仅纳入报告各代MFx治疗软骨缺损的功能、放射学、组织学结果或并发症的随机对照试验(RCT)。在Stata中进行网状Meta分析(NMA),并采用Cochrane对NMA方法的信心评估证据。
分析纳入44项RCT,患者平均年龄为39.40(±9.46)岁。将其他各代结果与作为固定对照的MFx-I进行比较时,我们注意到在1年、2年和5年时间点结束时,MFx-III在疼痛控制和功能结果(膝关节损伤和骨关节炎疗效评分(KOOS)、国际膝关节文献委员会(IKDC)评分和辛辛那提评分)方面有改善趋势,尽管差异无统计学意义(>0.05)。我们还注意到在1年时,更高代微骨折的磁共振软骨修复组织评分有统计学意义(加权平均差:17.44,95%置信区间:0.72,34.16,P = 0.025;无显著异质性)。然而,2年时差异未持续存在。第二代和第三代MFx在MRI上有更好的缺损填充趋势,尽管差异无统计学意义(>0.05)。
利用无细胞和细胞成分增强其治疗软骨缺损潜力的更高代传统MFx技术在临床和放射学结果方面仅显示出微小改善。